{
    "id": 27329,
    "fullName": "ATP1B1 - NRG1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ATP1B1-NRG1 results from the fusion of ATP1B1 and NRG1, which leads to increased Erk and Akt phosphorylation and proliferation in cell culture, and induces tumor formation in mouse models (PMID: 29802158). ATP1B1-NRG1 has been identified in cholangiocarcinoma (PMID: 28950338) and pancreatic ductal adenocarcinoma (PMID: 29802158).",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10433,
                    "pubMedId": 28950338,
                    "title": "Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28950338"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 481,
        "geneSymbol": "ATP1B1",
        "terms": [
            "ATP1B1",
            "ATP1B"
        ]
    },
    "variant": "ATP1B1 - NRG1",
    "createDate": "12/14/2017",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3084,
                "geneSymbol": "NRG1",
                "terms": [
                    "NRG1",
                    "ARIA",
                    "GGF",
                    "GGF2",
                    "HGL",
                    "HRG",
                    "HRG1",
                    "HRGA",
                    "MST131",
                    "MSTP131",
                    "NDF",
                    "NRG1-IT2",
                    "SMDF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 12566,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cholangiocarcinoma harboring ATP1B1-NRG1 demonstrated a lasting response when treated with Gilotrif (afatinib) (PMID: 28950338).",
            "molecularProfile": {
                "id": 28757,
                "profileName": "ATP1B1 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10433,
                    "pubMedId": 28950338,
                    "title": "Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28950338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18699,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in significant radiologic response and clinical improvement 4 weeks after initiation of therapy in a patient with pancreatic ductal adenocarcinoma harboring an ATP1B1-NRG1 fusion, but his disease progressed at 5.5 months (PMID: 31068372).",
            "molecularProfile": {
                "id": 28757,
                "profileName": "ATP1B1 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16389,
                    "pubMedId": 31068372,
                    "title": "NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068372"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18700,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in significant radiologic response and clinical improvement 4 weeks after initiation of therapy in a patient with KRAS wild-type pancreatic ductal adenocarcinoma harboring an ATP1B1-NRG1 fusion, however, his disease progressed at 5.5 months (PMID: 31068372).",
            "molecularProfile": {
                "id": 31309,
                "profileName": "ATP1B1 - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16389,
                    "pubMedId": 31068372,
                    "title": "NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068372"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15907,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a\u00a0patient with KRAS wild-type pancreatic ductal adenocarcinoma\u00a0harboring\u00a0an ATP1B1-NRG1 fusion had reduced\u00a0liver\u00a0metastases size at 7 weeks when treated with Gilotrif (afatinib), however, disease progression was evident\u00a0after\u00a03 months;\u00a0and\u00a0Gilotrif (afatinib) reduced AKT and ERK signaling in cultured pancreatic cells\u00a0expressing an\u00a0ATP1B1-NRG1 fusion (PMID: 29802158).",
            "molecularProfile": {
                "id": 31309,
                "profileName": "ATP1B1 - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28757,
            "profileName": "ATP1B1 - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31309,
            "profileName": "ATP1B1 - NRG1 KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}